- Home
- IMCC vs PHIO Comparison
IMCC vs PHIO Comparison
Compare IMCC & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- PHIO
- Stock Information
- Founded
- IMCC 1980
- PHIO 2011
- Country
- IMCC Israel
- PHIO United States
- Employees
- IMCC N/A
- PHIO N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- PHIO Health Care
- Exchange
- IMCC Nasdaq
- PHIO Nasdaq
- Market Cap
- IMCC 11.8M
- PHIO 10.2M
- IPO Year
- IMCC N/A
- PHIO N/A
- Fundamental
- Price
- IMCC $2.56
- PHIO $2.11
- Analyst Decision
- IMCC
- PHIO Strong Buy
- Analyst Count
- IMCC 0
- PHIO 3
- Target Price
- IMCC N/A
- PHIO $10.67
- AVG Volume (30 Days)
- IMCC 50.5K
- PHIO 2.7M
- Earning Date
- IMCC 08-12-2025
- PHIO 08-14-2025
- Dividend Yield
- IMCC N/A
- PHIO N/A
- EPS Growth
- IMCC N/A
- PHIO N/A
- EPS
- IMCC N/A
- PHIO N/A
- Revenue
- IMCC $38,430,631.00
- PHIO N/A
- Revenue This Year
- IMCC $47.12
- PHIO N/A
- Revenue Next Year
- IMCC $12.83
- PHIO N/A
- P/E Ratio
- IMCC N/A
- PHIO N/A
- Revenue Growth
- IMCC 5.08
- PHIO N/A
- 52 Week Low
- IMCC $1.29
- PHIO $0.97
- 52 Week High
- IMCC $7.12
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- IMCC 45.77
- PHIO 40.77
- Support Level
- IMCC $2.52
- PHIO $2.03
- Resistance Level
- IMCC $3.13
- PHIO $2.29
- Average True Range (ATR)
- IMCC 0.33
- PHIO 0.16
- MACD
- IMCC -0.00
- PHIO -0.03
- Stochastic Oscillator
- IMCC 29.87
- PHIO 22.39
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.